ArticleVaccines2021

Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study.

Alexandr Zurochka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.